news – Page 65 – Medxy AI

Australian Dermatologists’ Perspectives on AI Integration: Trust, Benefits, and Barriers in Clinical Practice

By MedXY 09/28/2025

A recent survey reveals that Australian dermatologists are cautiously integrating AI into practice, prioritizing accuracy and trust for diagnostic use, with optimism about AI enhancing patient access and reducing workload but concerns about data transparency and corporate influence.

Critical Care Emergency Medicine news Specialties

Enhancing Communication in Trauma ICUs with the Best Case/Worst Case Tool: A Feasible Approach to Improve Prognostic Discussions

By MedXY 09/28/2025

The Best Case/Worst Case-ICU communication tool supports trauma ICU teams in effectively discussing prognoses with families, improving decision-making and reducing distress, though implementation faces practical barriers.

news Pediatrics Specialties

Progression of Transdiagnostic Clinical Stages From Childhood to Young Adulthood: Evidence and Implications

By MedXY 09/28/2025

This review synthesizes cohort and longitudinal studies supporting the progression of transdiagnostic mental health stages from familial risk in childhood through early symptoms in adolescence to clinically significant disorders in young adulthood, independent of early life confounders.

news Oncology Specialties

Painful Sunburns and Their Link to Cutaneous Squamous Cell Carcinoma: Insights from a Comprehensive Meta-Analysis

By MedXY 09/28/2025

A meta-analysis of over 320,000 participants confirms that painful, blistering sunburns, especially in childhood, significantly increase the risk of cutaneous squamous cell carcinoma (cSCC).

news Public Health Specialties

Effective Communication of Medical Numerical Information: Guidelines for Researchers

By MedXY 09/28/2025

This article outlines recommended guidelines for researchers reporting studies on communicating health-related numbers to lay audiences, highlighting common reporting issues and proposing seven key recommendations to improve clarity and synthesis of evidence.

news Pediatrics Public Health Specialties

Navigating Childhood Insurance in the US: Insights into Medicaid, CHIP, and Uninsurance Dynamics

By MedXY 09/28/2025

A simulation study reveals that 75% of US children experience publicly subsidized insurance or uninsurance periods by age 18, highlighting the impact of state Medicaid policies on pediatric coverage gaps.

Clinical Updates news

Assessing the Value of Preoperative Antibiotics in Uncomplicated Acute Appendicitis: Insights from the PERFECT-Antibiotics Trial

By MedXY 09/28/2025

Preoperative antibiotics in uncomplicated acute appendicitis do not reduce appendiceal perforation risk but lower surgical site infections. This large multicenter trial clarifies their limited role while awaiting timely appendectomy.

Clinical Updates Neurology news

Clinically Meaningful Changes in Cognitive and Functional Measures Early in Alzheimer’s Disease: Insights from Population-Based Cohorts

By MedXY 09/28/2025

This review synthesizes evidence on clinically meaningful within-patient changes in cognitive and functional assessments among individuals transitioning to mild cognitive impairment (MCI), highlighting implications for clinical trials and early intervention in Alzheimer's disease and related dementias (ADRD).

AI news Oncology Radiology Specialties

Advancing Precision Medicine in Hepatocellular Carcinoma: Machine Learning Radiomic Models Surpass Clinical Biomarkers in Predicting Immunotherapy Outcomes

By MedXY 09/27/2025

Integrated radiomic-clinical machine learning models outperform traditional clinical biomarkers in predicting survival and treatment response in unresectable hepatocellular carcinoma patients undergoing atezolizumab plus bevacizumab therapy.

Clinical Updates news

Age-Stratified Outcomes of Rivaroxaban Monotherapy in Atrial Fibrillation with Stable Coronary Artery Disease: Insights from the AFIRE Trial

By MedXY 09/27/2025

This post hoc AFIRE trial analysis shows rivaroxaban monotherapy reduces major cardiovascular events and major bleeding across age groups in AF with stable CAD, with notable age-related efficacy and safety trends warranting further research.

Cardiology news

Long-Term Survival Outcomes After Initial Stress Testing Versus Coronary CTA in Suspected CAD: Insights from the PROMISE Trial

By MedXY 09/27/2025

The PROMISE trial's 10-year follow-up shows no difference in all-cause or cardiovascular mortality between initial functional stress testing and anatomic coronary CTA in symptomatic patients with suspected coronary artery disease.

Cardiology news Specialties

High Prevalence and Clinical Impact of Sleep Apnea in Hypertrophic Cardiomyopathy: Insights from a Prospective Cohort Study

By MedXY 09/27/2025

Sleep disordered breathing affects over half of patients with hypertrophic cardiomyopathy, correlating with worsening myocardial remodeling, diastolic dysfunction, and subclinical myocardial injury, underscoring the need for clinical trials on intervention.

Cardiology Clinical Updates news Radiology Specialties

Advancing Noninvasive Imaging in Assessing Hemodynamic Significance of Right Coronary Artery Anomalies

By MedXY 09/27/2025

This article reviews a prospective study evaluating noninvasive anatomical and functional imaging methods to determine hemodynamic significance in right anomalous aortic origin of a coronary artery (R-AAOCA), proposing a stepwise diagnostic approach to reduce invasive testing.

Cardiology news Radiology Specialties

Linking Retinal Microvasculature to Silent Coronary Atherosclerosis: Insights from Optical Coherence Tomography Angiography

By MedXY 09/27/2025

Reduced retinal parafoveal vascular density measured by OCTA independently correlates with subclinical coronary atherosclerosis, revealing a novel noninvasive biomarker for cardiovascular risk assessment beyond traditional factors.

news Public Health Respiratory

Evaluating the 23-Valent Pneumococcal Polysaccharide Vaccine for Cardiovascular Event Prevention: Insights from a Landmark Randomized Trial

By MedXY 09/27/2025

A large randomized clinical trial demonstrated that the 23-valent pneumococcal polysaccharide vaccine (PPV23) did not significantly reduce fatal or nonfatal acute coronary syndrome and ischemic stroke among middle-aged adults at increased cardiovascular risk over seven years of follow-up.

news Public Health Respiratory Specialties

Rare Case of Multifocal Cutaneous Tuberculosis in an Immunocompetent Patient

By MedXY 09/27/2025

We present a case of multifocal cutaneous tuberculosis in a 35-year-old immunocompetent woman, highlighting diagnostic challenges and effective management with standard anti-tubercular therapy.

Cardiology Clinical Updates Neurology news

Electrophysiological Study Surpasses ECG in Predicting Life-Threatening Conduction Delays in Myotonic Dystrophy Type 1

By MedXY 09/27/2025

In patients with myotonic dystrophy type 1 (DM1), electrophysiological study (EPS) using the His-ventricular (HV) interval is superior to electrocardiogram (ECG) in predicting major bradyarrhythmic events, suggesting enhanced risk stratification with EPS-guided thresholds.

Cardiology Clinical Updates news

Rising Trends into Transcatheter Aortic Valve Reinterventions: Redo TAVR and Explant Procedures from 2012 to 2024

By MedXY 09/27/2025

This article reviews increasing volumes and incidence of transcatheter aortic valve replacement (TAVR) reinterventions, analyzing procedural trends of redo TAVR and TAVR explant over the past decade, emphasizing implications for clinical practice and future strategies.

Cardiology Clinical Updates news

Systolic Blood Pressure as a Key Modifier of Survival Benefit from Microaxial Flow Pump Therapy in Infarct-Related Cardiogenic Shock: Insights from the DanGer Shock Trial

By MedXY 09/27/2025

This post hoc analysis of the DanGer Shock trial reveals that low systolic blood pressure at treatment initiation markedly enhances survival benefit from microaxial flow pump support in infarct-related cardiogenic shock.

Diabetes & Endocrinology news Specialties

Orforglipron: A Promising Oral GLP-1 Receptor Agonist for Long-Term Obesity Management

By MedXY 09/27/2025

Orforglipron, a novel oral GLP-1 receptor agonist, demonstrated significant and sustained weight reduction in obese adults without diabetes in a 72-week phase 3 trial, with a tolerable safety profile consistent with existing GLP-1 therapies.